Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Phase 1 (NCT04263090)
This is an open-label, dose-escalating Phase I study followed by a Phase 2a dose-expansion phase to study the combination of rigosertib and nivolumab in metastatic Kirsten rat sarcoma positive (KRAS+) lung adenocarcinoma patients who have progressed on standard first line treatment.
Icahn School of Medicine at Mount Sinai
Onconova Therapeutics, Inc.